Phillip Minar, MD, MS
- Medical Director, Shubert-Martin Inflammatory Bowel Disease Center
- Program Director, Advanced Pediatric IBD Fellowship Training
- Associate Professor, UC Department of Pediatrics
- phillip.minar@cchmc.org
- Board Certified
About
BA: Duquesne University, Pittsburgh, PA.
MS: Clinical and Translational Research, University of Cincinnati, Cincinnati, OH.
MD: Medical College of Wisconsin, Milwaukee, WI.
Residency: Pediatrics, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, WI.
Fellowship: Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Certification: General Pediatrics; Pediatric Gastroenterology.
Interests
Pediatric inflammatory bowel disease; evidence-based care for children and young adults with IBD; sustained, prednisone-free clinical remission
Services and Specialties
Interests
Application of personalized medicine in the care of children and young adults with IBD through the discovery of surrogate biomarkers of intestinal inflammation; sensitive and specific pharmacodynamic biomarker, neutrophil CD64; innovative pharmacokinetic dosing platform, RoadMAB; personalized dosing of biologic therapies for patients with IBD; novel method to dose infliximab (guided by RoadMAB) from the start of treatment and throughout the maintenance phase to assess both the effectiveness and safety of model-informed precision dosing.
Research Areas
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics. Inflammatory Bowel Diseases. 2024; 30:1678-1685.
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease. The American Journal of Gastroenterology (Elsevier). 2024; 119:1110-1116.
Challenges in IBD Research 2024: Pragmatic Clinical Research. Inflammatory Bowel Diseases. 2024; 30:S55-S66.
958 ATTAINING EARLY ANTI-TNF EXPOSURE TARGETS IS ASSOCIATED WITH IMPROVED RATES OF ENDOSCOPIC HEALING AND TRANSMURAL HEALING IN CHILDREN WITH CROHN'S DISEASE. Gastroenterology. 2024; 166:s-226-s-227.
748 EXTENSIVE PROTEOMIC ANALYSIS IDENTIFIES A CROHN'S DISEASE CORE PROTEOME AND ANTI-TNF TREATMENT RESPONSE PROFILE FOR CHILDREN WITH CROHN'S DISEASE. Gastroenterology. 2024; 166:s-177-s-178.
Precise infliximab exposure and pharmacodynamic control to achieve deep remission in paediatric Crohn's disease (REMODEL-CD): study protocol for a multicentre, open-label, pragmatic clinical trial in the USA. BMJ Open. 2024; 14:e077193.
Acute pancreatitis is associated with gut dysbiosis in children. Digestive and Liver Disease. 2024; 56:444-450.
Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports. 2023; 25:323-332.
Acute pancreatitis is associated with gut dysbiosis in children. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]. 2023; 23:e3-e4.
From the Blog
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey